The influence of blood group differences in allogeneic hematopoietic peripheral blood progenitor cell transplantation

BACKGROUND: Severe immunohematologic complications after ABO‐mismatched allogeneic blood peripheral blood progenitor cell (PBPC) transplantation (PBPCT), including pure red cell aplasia and immune hemolysis, have been described. Although several studies have addressed this issue, the clinical influence of blood group differences on transfusion requirements and survival is still discussed controversially, especially in the case of PBPCT.

[1]  J. Sierra,et al.  Impact of ABO incompatibility on allogeneic peripheral blood progenitor cell transplantation after reduced intensity conditioning , 2004, Transfusion.

[2]  H. Greinix,et al.  ABO mismatch increases transplant‐related morbidity and mortality in patients given nonmyeloablative allogeneic HPC transplantation , 2003, Transfusion.

[3]  L. Dümbgen,et al.  Probability of anti‐D development in D− patients receiving D+ RBCs , 2003, Transfusion.

[4]  J. Liesveld,et al.  ABO incompatibility between donor and recipient and clinical outcomes in allogeneic stem cell transplantation. , 2003, Leukemia research.

[5]  Je-Hwan Lee,et al.  Changes of isoagglutinin titres after ABO‐incompatible allogeneic stem cell transplantation , 2003, British journal of haematology.

[6]  R. Storb,et al.  Engraftment of early erythroid progenitors is not delayed after non‐myeloablative major ABO‐incompatible haematopoietic stem cell transplantation , 2002, British journal of haematology.

[7]  H. Greinix,et al.  Severe immune hemolysis after minor ABO‐mismatched allogeneic peripheral blood progenitor cell transplantation occurs more frequently after nonmyeloablative than myeloablative conditioning , 2002, Transfusion.

[8]  B. Horisberger,et al.  Current trends in hematopoietic stem cell transplantation in Europe. , 2002, Blood.

[9]  A. Gratwohl,et al.  Consequences of ABO incompatibility in allogeneic hematopoietic stem cell transplantation , 2002, Bone Marrow Transplantation.

[10]  S. Singhal,et al.  Does donor–recipient ABO incompatibility protect against relapse after allogeneic bone marrow transplantation in first remission acute myeloid leukemia? , 2002, Bone Marrow Transplantation.

[11]  R. Storb,et al.  Decreased transfusion requirements for patients receiving nonmyeloablative compared with conventional peripheral blood stem cell transplants from HLA-identical siblings. , 2001, Blood.

[12]  N. Schmitz,et al.  Second German consensus on immunogenetic donor search for allotransplantation of hematopoietic stem cells , 2001, Annals of Hematology.

[13]  A. Barrett,et al.  Delayed donor red cell chimerism and pure red cell aplasia following major ABO-incompatible nonmyeloablative hematopoietic stem cell transplantation. , 2001, Blood.

[14]  L. Rydberg.  ABO‐incompatibility in solid organ transplantation , 2001, Transfusion medicine.

[15]  J. Radich,et al.  Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. , 2001, Blood.

[16]  G. Stussi,et al.  Graft‐versus‐host disease and survival after ABO‐incompatible allogeneic bone marrow transplantation: a single‐centre experience , 2001, British journal of haematology.

[17]  A. Barrett,et al.  Massive immune haemolysis after allogeneic peripheral blood stem cell transplantation with minor ABO incompatibility , 2001, British journal of haematology.

[18]  R Storb,et al.  Transplantation of bone marrow as compared with peripheral-blood cells from HLA-identical relatives in patients with hematologic cancers. , 2001, The New England journal of medicine.

[19]  J. de la Rubia,et al.  Development of non‐ABO RBC alloantibodies in patients undergoing allogeneic HPC transplantation. Is ABO incompatibility a predisposing factor? , 2001, Transfusion.

[20]  R. Storb,et al.  Graft-versus-host disease and donor-directed hemagglutinin titers after ABO-mismatched related and unrelated marrow allografts: evidence for a graft-versus-plasma cell effect. , 2000, Blood.

[21]  P. Höcker,et al.  Regeneration of erythropoiesis after related‐ and unrelated‐donor BMT or peripheral blood HPC transplantation: a major ABO mismatch means problems , 2000, Transfusion.

[22]  S. Singhal,et al.  Allogeneic blood and bone-marrow stem-cell transplantation in haematological malignant diseases: a randomised trial , 2000, The Lancet.

[23]  S. Kim,et al.  Anti-A isoagglutinin as a risk factor for the development of pure red cell aplasia after major ABO-incompatible allogeneic bone marrow transplantation , 2000, Bone Marrow Transplantation.

[24]  R. Childs,et al.  Molecular remission of chronic myeloid leukaemia following a non‐myeloablative allogeneic peripheral blood stem cell transplant: in vivo and in vitro evidence for a graft‐versus‐leukaemia effect , 1999, British journal of haematology.

[25]  N. Hensel,et al.  Successful treatment of metastatic renal cell carcinoma with a nonmyeloablative allogeneic peripheral-blood progenitor-cell transplant: evidence for a graft-versus-tumor effect. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  M. Tanner,et al.  The expression of human blood group antigens during erythropoiesis in a cell culture system. , 1999, Blood.

[27]  R. Benjamin,et al.  ABO incompatibility as an adverse risk factor for survival after allogeneic bone marrow transplantation , 1999, Transfusion.

[28]  N. Schmitz,et al.  Allogeneic bone marrow transplantation vs filgrastim-mobilised peripheral blood progenitor cell transplantation in patients with early leukaemia: first results of a randomised multicentre trial of the European Group for Blood and Marrow Transplantation , 1998, Bone Marrow Transplantation.

[29]  A. Nagler,et al.  Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. , 1998, Blood.

[30]  E. Estey,et al.  Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy. , 1997, Blood.

[31]  S. Singhal,et al.  Transfusion requirements after bone marrow transplantation from HLA-identical siblings: effects of donor-recipient ABO incompatibility. , 1996, Bone marrow transplantation.

[32]  A. Nagler,et al.  Passenger B-lymphocyte-induced severe hemolytic disease after allogeneic peripheral blood stem cell transplantation. , 1996, Blood.

[33]  D. Weisdorf,et al.  Exchange transfusion the hard way: massive hemolysis following transplantation of bone marrow with minor ABO incompatibility , 1996, Transfusion.

[34]  A. de Man,et al.  Erythrocyte repopulation after major ABO incompatible transplantation with lymphocyte-depleted bone marrow. , 1995, Bone marrow transplantation.

[35]  N. Schmitz,et al.  Primary transplantation of allogeneic peripheral blood progenitor cells mobilized by filgrastim (granulocyte colony-stimulating factor) , 1995, Blood.

[36]  Richard,et al.  Hemolysis of transfused group O red blood cells in minor ABO-incompatible unrelated-donor bone marrow transplants in patients receiving cyclosporine without posttransplant methotrexate. , 1992, Blood.

[37]  R. Krance,et al.  Donor-derived red blood cell antibodies and immune hemolysis after allogeneic bone marrow transplantation. , 1986, Blood.

[38]  R. Nuscher,et al.  Bone marrow transplantation. , 1977, The American journal of nursing.

[39]  R Storb,et al.  Bone-marrow transplantation (second of two parts). , 1975, The New England journal of medicine.

[40]  P. Neiman,et al.  CLINICAL MANIFESTATIONS OF GRAFT‐VERSUS-HOST DISEASE IN HUMAN RECIPIENTS OF MARROW FROM HL‐A-MATCHED SIBLING DONOR,S , 1974, Transplantation.

[41]  Susan Buck-Morss,et al.  Exchange , 1919, The Indian medical gazette.